Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
(NASDAQ:IDYA) Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US Darovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical need IDEAYA will...
Related Questions
How will the exclusive licensing of darovasertib outside the US affect IDEAYA's future revenue projections and valuation?
What are the anticipated timelines for regulatory approvals and commercialization, and how might delays impact the stock price?
How does IDEAYA's uveal melanoma candidate compare to existing therapies and other pipeline competitors in terms of efficacy, safety, and market potential?